Fangjie Liu

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Fraction dose escalation of split-course concurrent chemoradiotherapy following induction chemo-immunotherapy in unresectable locally advanced oesophageal squamous carcinoma in China (GASTO-10102): a single-centre phase 1 study.

Fraction dose escalation of split-course concurrent chemoradiotherapy following induction chemo-immunotherapy in unresectable locally advanced oesophageal squamous carcinoma in China (GASTO-10102): a single-centre phase 1 study.

Journal: EClinicalMedicine
Published: January 07, 2026

In Situ Exsolved Ni Nanoparticles From Pr0.5Sr0.5Ti0.5Mn0.5O3 with Varying Ni Doping Levels for Direct Methane Solid Oxide Fuel Cells.

In Situ Exsolved Ni Nanoparticles From Pr0.5Sr0.5Ti0.5Mn0.5O3 with Varying Ni Doping Levels for Direct Methane Solid Oxide Fuel Cells.

Journal: Small (Weinheim an der Bergstrasse, Germany)
Published: October 17, 2025

Magnetic resonance-guided split-course hypo-fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer: A single arm, phase 2 study.

Magnetic resonance-guided split-course hypo-fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer: A single arm, phase 2 study.

Journal: Cancer
Published: August 07, 2025

Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study.

Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study.

Journal: Frontiers in immunology
Published: August 06, 2025

Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053).

Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053).

Journal: Cancer communications (London, England)
Published: April 14, 2025

Early Nutritional Intervention in Patients with Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: A Phase II Prospective Study.

Early Nutritional Intervention in Patients with Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: A Phase II Prospective Study.

Journal: Nutrients
Published: March 25, 2025

Abbreviated dynamic total-body [18F]FDG PET/CT protocols for predicting response in locally advanced non-small cell lung cancer via Patlak-Ki analysis.

Abbreviated dynamic total-body [18F]FDG PET/CT protocols for predicting response in locally advanced non-small cell lung cancer via Patlak-Ki analysis.

Journal: Quantitative imaging in medicine and surgery
Published: February 11, 2025

Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial.

Efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy for brain metastases in non-small cell lung cancer (GASTO-1075): a single-arm, phase 2 trial.

Journal: EClinicalMedicine
Published: January 14, 2025

Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial.

Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial.

Journal: Signal transduction and targeted therapy
Published: November 25, 2024

Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial.

Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial.

Journal: EClinicalMedicine
Published: November 14, 2024

Stability of gut microbiota in non-small cell lung cancer patients during chemoradiotherapy and its association with radiation pneumonitis.

Stability of gut microbiota in non-small cell lung cancer patients during chemoradiotherapy and its association with radiation pneumonitis.

Journal: iScience
Published: November 07, 2024

Artificial Intelligence Technologies for Managing High-Risk Patients With Immune-Related Adverse Events and Optimizing Timing.

Artificial Intelligence Technologies for Managing High-Risk Patients With Immune-Related Adverse Events and Optimizing Timing.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 31, 2024
Showing 1-12 of 35

Last Updated: 09/26/2026